Zonisamide Versus Propranolol in Migraine

PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

April 20, 2025

Conditions
Migraine
Interventions
DRUG

Zonisamide 50 MG

"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."

DRUG

Propranolol

"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."

Trial Locations (1)

33511

RECRUITING

Kafr Elsheikh University Hospital, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER